USChinaHealthcare.comSystems, policy, strategy
简体中文
Regulatory index

Regulatory Pathways Index

The Regulatory Pathways Index groups FDA, NMPA, drug, device, diagnostic, clinical trial, GCP, ethics, postmarket, pharmacovigilance, real-world evidence, accelerated approval, AI medical device, SaMD, and cybersecurity pages.

IndexNavigation
Reference guideCurated orientation

Purpose

The Regulatory Pathways Index groups FDA, NMPA, drug, device, diagnostic, clinical trial, GCP, ethics, postmarket, pharmacovigilance, real-world evidence, accelerated approval, AI medical device, SaMD, and cybersecurity pages.

Plain-English answer

The Regulatory Pathways Index groups FDA, NMPA, drug, device, diagnostic, clinical trial, GCP, ethics, postmarket, pharmacovigilance, real-world evidence, accelerated approval, AI medical device, SaMD, and cybersecurity pages.

When to use this page

Use this index when a question concerns approval route, evidence standard, lifecycle obligation, or regulatory localization.

Pages in this cluster

Postmarket Support in the U.S. Healthcare MarketRegulatory Pathways IndexRegulatory Sequencing for China Market EntryFDA 与 NMPA 的区别FDA 医疗器械路径图FDA 批准不等于美国市场成功Real-World Evidence 是什么

Evidence context

Use this page as an orientation guide; detailed claims should be evaluated on the linked topic pages.

  • Regulatory pages require official agency materials, legal sources, guidance, clinical evidence, and postmarket obligations.
  • Follow the linked topic pages for definitions, evidence context, and analytical frameworks.
  • Use the methods pages for evidence grading, citation style, and Chinese-language access policy.